Linguistic, reliable, and valid secondary efficacy measures are important in clinical settings and studies. The aim of the study is to report test–retest reliability and construct validity of Turkish version of Myasthenia Gravis-Activities of Daily Living Scale (MG-ADL-T) in Myasthenia Gravis (MG) patients. Fifty-two ocular and generalized individuals with MG, applying to rehabilitation center, were included in the study. MG-ADL-T, MG quality-of-life questionnaire (MG-QoL), MG composite (MGC), quantitative MG score (QMGS), and pulmonary function test were administered. Reliability was assessed with intraclass correlation coefficient (ICC) and Cronbach’s alpha. Spearman correlation test and receiver operating characteristic (ROC) analysis were performed for construct validity. MG-ADL-T had fair internal consistency (Cronbach’s α = .67), excellent test–retest reliability (ICC = 0.96) and moderate construct validity (MG-QoL, r = 0.59; QMGS, r = .58; MGC, r = .68). MG-ADL, a unique scale that evaluates activities of daily living (ADL), has good test–retest reliability and construct validity in Turkish MG patients.
AlanazyM. H.AbuzinadahA. R.MuayqilT. (2019). Translation and validation of the Arabic version of the myasthenia gravis activities of daily living scale. Muscle & Nerve, 59(5), 583–586. https://doi.org/10.1002/mus.26435
2.
BeatonD. E.BombardierC.GuilleminF.FerrazM. B. (2000). Guidelines for the process of cross-cultural adaptation of self-report measures. Spine, 25(24), 3186–3191. https://doi.org/10.1097/00007632-200012150-00014
3.
BedlackR. S.SimelD. L.BosworthH.SamsaG.Tucker-LipscombB.SandersD. B. (2005). Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity. Neurology, 64(11), 1968–1970. https://doi.org/10.1212/01.WNL.0000163988.28892.79
4.
BrymanA.CramerD. (2000). Quantitative data analysis with SPSS release 8 for Windows : A guide for social scientists. Routledge.
5.
BurnsT. M. (2010). History of outcome measures for myasthenia gravis. Muscle & Nerve, 42(1), 5–13. https://doi.org/10.1002/mus.21713
6.
BurnsT. M.ConawayM.SandersD. B. (2010a). The MG composite: A valid and reliable outcome measure for myasthenia gravis. Neurology, 74(18), 1434–1440. https://doi.org/10.1212/wnl.0b013e3181dc1b1e
7.
BurnsT. M.ConawayM. R.CutterG. R.SandersD. B. (2008). Construction of an efficient evaluative instrument for myasthenia gravis: The MG composite. Muscle & Nerve, 38(6), 1553–1562. https://doi.org/10.1002/mus.21185
8.
BurnsT. M.GrouseC.WolfeG. I.ConawayM. R.SandersD. B. (2010b). The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle & Nerve, 43(1), 14–18. https://doi.org/10.1002/mus.21883
GilhusN. E.SkeieG. O.RomiF.LazaridisK.ZisimopoulouP.TzartosS. (2016). Myasthenia gravis-autoantibody characteristics and their implications for therapy. Nature Reviews Neurology, 12(5), 259–268. https://doi.org/10.1038/nrneurol.2016.44
12.
HowardJ. F.FreimerM.ObrienF.WangJ. J.CollinsS. R.KisselJ. T. (2017). QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. Muscle & Nerve, 56(2), 328–330. https://doi.org/10.1002/mus.25529
13.
JaretzkiA.BarohnR. J.ErnstoffR. M.KaminskiH. J.KeeseyJ. C.PennA. S.SandersD. B. (2000). Myasthenia gravis: Recommendations for clinical research standards. Neurology, 55(1), 16–23. https://doi.org/10.1212/wnl.55.1.16
14.
JeongA.MinJ.-H.KangY. K.KimJ.ChoiM.SeokJ. M.KimB. J. (2018). Factors associated with quality of life of people with myasthenia gravis. PLOS ONE, 13(11), Article e0206754. https://doi.org/10.1371/journal.pone.0206754
15.
KingM. T. (2011). A point of minimal important difference (MID): A critique of terminology and methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 171–184. https://doi.org/10.1586/erp.11.9
16.
KumarR.IndrayanA. (2011). Receiver operating characteristic (ROC) curve for medical researchers. Indian Pediatrics, 48(4), 277–287. https://doi.org/10.1007/s13312-011-0055-4
17.
LeeH. L.MinJ.-H.SeokJ. M.ChoE. B.ChoH. J.KimY.-D.KimB. J. (2017). Physician- and self-assessed myasthenia gravis activities of daily living score. Muscle & Nerve, 57(3), 419–422. https://doi.org/10.1002/mus.25764
MokkinkL. B.TerweeC. B.PatrickD. L.AlonsoJ.StratfordP. W.KnolD. L.. . . VetH. C. W. D. (2010). The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Quality of Life Research, 19(4), 539–549. https://doi.org/10.1007/s11136-010-9606-8
20.
MukakaM. (2012). Statistics Corner: A guide to appropriate use of Correlation coefficient in medical research. Malawi Medical Journal, 24(3), 69–71. https://doi.org/10.4314/mmj.v24i3
21.
MuppidiS. (2012). The myasthenia gravis-specific activities of daily living profile. Annals of the New York Academy of Sciences, 1274(1), 114–119. https://doi.org/10.1111/j.1749-6632.2012.06817.x
MuppidiS.WolfeG. I.ConawayM.BurnsT. M. (2011). MG-ADL: Still a relevant outcome measure. Muscle & Nerve, 44(5), 727–731. https://doi.org/10.1002/mus.22140
24.
RaggiA.AntozziC.BaggiF.LeonardiM.MaggiL.MantegazzaR. (2017). Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients. Neurological Sciences, 38(11), 1927–1931. https://doi.org/10.1007/s10072-017-3083-6
25.
RaggiA.LeonardiM.SchiavolinS.AntozziC.BrennaG.MaggiL.MantegazzaR. (2016). Validation of the MG-DIS: A disability assessment for myasthenia gravis. Journal of Neurology, 263(5), 871–882. https://doi.org/10.1007/s00415-016-8072-9
26.
RozmilowskaI. M.Adamczyk-SowaM. H.CzyzewskiD. (2018). The myasthenia gravis-specific activities of daily living scale as a useful outcome measure and in routine clinical management in Polish patients. Neurologia i Neurochirurgia Polska, 52(3), 368–373. https://doi.org/10.1016/j.pjnns.2017.12.012
27.
SalciY.KaranfilE.BalkanA. F.KütükçüE. Ç.CerenA. N.AyvatF.Bekircan-KurtC. E.ArmutluK. (2018). Functional exercise capacity evaluated by timed walk tests in myasthenia gravis. Muscle & Nerve, 59(2), 208–212. https://doi.org/10.1002/mus.26345
StreinerD. L. (2003). Starting at the beginning: An introduction to coefficient alpha and internal consistency. Journal of Personality Assessment, 80(1), 99–103. https://doi.org/10.1207/s15327752jpa8001_18
30.
StreinerD. L.CairneyJ.NormanG. R. (2015). Health measurement scales: A practical guide to their development and use. Oxford University Press.
31.
TaşcilarN. F.SaraçliÖ.KurçerM. A.AnkaraliH.EmreU. (2016). Reliability and validity of the Turkish version of myasthenia gravis-quality of life questionnaire-15 item. Turkish Journal of Medical Sciences, 46, 1107–1113. https://doi.org/10.3906/sag-1504-97
32.
TascilarN. F.SaracliO.KurcerM. A.AnkaraliH.EmreU. (2017). Is there any relationship between quality of life and polysomnographically detected sleep parameters/disorders in stable myasthenia gravis?Acta Neurologica Belgica, 118(1), 29–37. https://doi.org/10.1007/s13760-017-0787-6
33.
WolfeG. I.HerbelinL.NationsS. P.FosterB.BryanW. W.BarohnR. J. (1999). Myasthenia gravis activities of daily living profile. Neurology, 52(7), 1487–1487. https://doi.org/10.1212/wnl.52.7.1487
